Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MGX

Metagenomi Inc.

Sep 13 • 04:00PM ET

2.70

Dollar change +0.01
Percentage change 0.37	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWM VTWO IWO SCHA IWN IWC VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.52	Insider Own	50.47%	Shs Outstand	37.47M	Perf Week	-0.74%
Market Cap	101.06M	Forward P/E	-	EPS next Y	-2.90	Insider Trans	-0.03%	Shs Float	18.54M	Perf Month	-12.90%
Income	-75.00M	PEG	-	EPS next Q	-0.78	Inst Own	25.91%	Short Float	1.17%	Perf Quarter	-55.00%
Sales	55.93M	P/S	1.81	EPS this Y	85.26%	Inst Trans	-	Short Ratio	2.25	Perf Half Y	-74.81%
Book/sh	7.19	P/B	0.38	EPS next Y	1.82%	ROA	-	Short Interest	0.22M	Perf Year	-
Cash/sh	8.01	P/C	0.34	EPS next 5Y	-	ROE	-	52W Range	2.63 - 12.74	Perf YTD	-73.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-24.04%	52W High	-78.81%	Beta	-
Dividend TTM	-	Quick Ratio	5.82	Sales past 5Y	3569.20%	Gross Margin	91.17%	52W Low	2.66%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	-	Oper. Margin	-158.21%	RSI (14)	36.95	Volatility	9.93% 9.33%
Employees	236	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-134.10%	Recom	1.29	Target Price	15.17
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	17.43%	Payout	-	Rel Volume	1.19	Prev Close	2.69
Sales Surprise	58.17%	EPS Surprise	55.62%	Sales Q/Q	76.48%	Earnings	Aug 14 BMO	Avg Volume	96.69K	Price	2.70
SMA20	-9.41%	SMA50	-26.85%	SMA200	-60.44%	Trades		Volume	114,656	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

Sep-03-24 04:05PM	Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months (GlobeNewswire)
Aug-29-24 07:32PM	Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference (GlobeNewswire)
Aug-28-24 06:10PM	Metagenomi to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-14-24 08:11AM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Loading…
08:05AM	Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 06:29PM	Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts (Insider Monkey) +10.54%
Aug-05-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm (GlobeNewswire)
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-29-24 04:00PM	Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
04:00PM	Loading…
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wapnick Pamela	Chief Financial Officer	Sep 05 '24	Sale	2.88	6,265	18,043	63,051	Sep 06 05:14 PM
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc.

Upgrade your FINVIZ experience